Max Scharping

Current Contract

Contract Value Index (CVI)

Earning a C+ Contract Value Index, Max Scharping's 1-year pact reflects how Pittsburgh valued the position market for a veteran interior lineman on a depth rotation. At $1.17M AAV, this deal sits squarely in the mid-to-low range for guards with his experience tier—affordable, non-committal, and built for short-term depth flexibility rather than long-term infrastructure investment. Scharping's B- performance grade heading into 2025 suggested he was holding his own in a reserve capacity, but the confirmed torn ACL that ended his campaign after just 3 games has fundamentally altered the calculus; the Steelers are now evaluating whether he can return to pre-injury form and, more critically, whether his recovery timeline aligns with their competitive needs. At 29 years old and seven seasons into his career, Scharping occupies classic journeyman territory—the type of veteran presence that has value when healthy but carries immediate roster risk when sidelined. The single-year structure actually works in his favor contractually, as it grants the Steelers clean exit options without dead cap complications, though the industry consensus from media and analysts frames his 2026 role as genuinely tenuous unless he demonstrates a swift and complete recovery during the offseason program. Given Pittsburgh's recent moves cutting multiple linemen and evaluating their offensive infrastructure, Scharping will need to prove both health and competitive relevance to secure meaningful snaps.

Contracts in the Same Value Band

Other same-position deals the Contract Value Index also places in the C band — a quick read on where Max's contract sits relative to comparable money.

Performance Analysis

Stacked against the G field, Max Scharping grades out at a B- performance level for Pittsburgh. The seven-year veteran posted limited production across the 2025 season, appearing in just 3 games before a torn ACL cut short his campaign and raised serious questions about both his health trajectory and roster security. Scharping's primary weakness is durability—the ACL injury represents a catastrophic setback for a depth-level interior lineman already operating on the margins of roster relevance, and at age 29, recovery timelines become exponentially steeper. At his modest $1.2M contract value, he lacks the financial protection of higher-salaried linemen, positioning him as expendable depth rather than essential infrastructure in Pittsburgh's offensive line equation. The media consensus frames this as an uphill battle: Scharping enters the offseason fighting for his professional future, and unless he demonstrates a full and timely recovery during the offseason program, the Steelers' recent roster activity—which has focused on defensive upgrades and depth signings—suggests Pittsburgh may move forward without him. For a career rotational player, an ACL tear at this stage of his arc is potentially career-altering; what happens next depends entirely on whether he can return to meaningful availability.

How Max Compares at the Position

Max Scharping ranks 32nd of 172 graded gs by performance. That slots Max between Kevin Dotson (B-) just ahead and Ben Powers (C+) just behind.

Current Sentiment

Max Scharping enters the 2026 offseason with an F-grade public perception, largely shaped by the devastating ACL tear that cut short his 2025 campaign and cast serious doubt over his future in Pittsburgh. The injury narrative has completely overshadowed any previous momentum the seven-year veteran had built, with media coverage painting a pragmatic but concerning picture of his roster security. At a modest $1.2M AAV, Scharping lacks the contractual protection of higher-paid linemen, positioning him as expendable depth rather than essential infrastructure for the Steelers' offensive line plans. Analysts and fans have adopted a sympathetic but realistic tone, acknowledging his veteran presence while questioning whether Pittsburgh can afford to wait on his recovery timeline given their competitive window. The consensus view frames Scharping as fighting an uphill battle to prove both his health and relevance, with most observers viewing his 2026 role as tenuous at best unless he demonstrates a remarkably swift and complete recovery.